One such initiative, Traceback Testing, which is funded by the National Cancer Institute, recommends offering at least BRCA1 and BRCA2 testing to all women diagnosed with ovarian cancer identified through pathology or tumor registries, along with follow-up testing and counseling of family members [128]. Here, BRCA1 is linked to ovarian carcinoma.